AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12540388 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HFat: > 65% of energy as lipids)
Number of subjects: 14
Study 12540388 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic high‐carbohydrate diet (HCho: 70‐75% of energy as carbohydrate)
Number of subjects: 14
Study 10068312 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic biopsy of astrocytomas with borderline histopathological features between WHO grades II and III
Number of subjects: 156
Study 10068312 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic biopsy of astrocytomas with borderline histopathological features between WHO grades III and IV
Number of subjects: 156
Study 10068312 — intervention group
Group type: COMPARATOR
Intervention: Control group of astrocytic tumors obtained at open surgery
Number of subjects: 156
Study 7578896 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil (600 mg b.i.d.)
Number of subjects: 20
Study 7578896 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 2182917 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic leg compression
Number of subjects: 310
Study 2182917 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 310
Study 421726 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 8
Study 421726 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 8
Study 421726 — intervention group
Group type: EXPERIMENTAL
Intervention: Procyclidine
Number of subjects: 8
Study 421726 — intervention group
Group type: COMPARATOR
Intervention: Lactose dummy
Number of subjects: 8
Study 421726 — intervention group
Group type: EXPERIMENTAL
Intervention: Television pupillometry
Number of subjects: 8
Study 421726 — intervention group
Group type: COMPARATOR
Intervention: Conventional autonomic function tests
Number of subjects: 8
Study 31897661 — intervention group
Group type: EXPERIMENTAL
Intervention: Oregovomab combined with standard-of-care (SOC) therapy
Number of subjects: 0
Study 31897661 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) therapy alone
Number of subjects: 0
Study 31897661 — intervention group
Group type: EXPERIMENTAL
Intervention: Oregovomab combined with SOC
Number of subjects: 0
Study 31897661 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline immune environment
Number of subjects: 0
Study 30565996 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early invasive evaluation (ICA within 12 hours)
Number of subjects: 2147
Study 30565996 — intervention group
Group type: COMPARATOR
Intervention: Standard invasive care (ICA within 48 to 72 hours)
Number of subjects: 2147
Study 30565996 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early invasive evaluation (ICA within 12 hours) among patients with GRACE risk score >140
Number of subjects: 2147
Study 30565996 — intervention group
Group type: COMPARATOR
Intervention: Standard invasive care (ICA within 48 to 72 hours) among patients with GRACE risk score >140
Number of subjects: 2147
Study 25567069 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazil nuts (288.75 µg/day) for 6 months
Number of subjects: 31
Study 25567069 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Brazil nuts)
Number of subjects: 31
Study 25354738 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 87
Study 25354738 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 87
Study 25354738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 22929242 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 24
Study 22929242 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 24
Study 22929242 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 24
Study 22929242 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine
Number of subjects: 24
Study 22929242 — intervention group
Group type: COMPARATOR
Intervention: Control tissue
Number of subjects: 24
Study 20813339 — intervention group
Group type: EXPERIMENTAL
Intervention: aMCI patients fulfilling biomarker criteria (CSF Aβ1‐42 ≤192 mg/mL or total‐tau/Aβ1‐42 >0.39)
Number of subjects: 400
Study 20813339 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (aMCI patients not requiring biomarker criteria)
Number of subjects: 400
Study 17683300 — intervention group
Group type: EXPERIMENTAL
Intervention: EBM educational intervention
Number of subjects: 75
Study 17683300 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 75
Study 16275831 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA
Number of subjects: 139
Study 16275831 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTB
Number of subjects: 139
Study 12145593 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (3 mg/kg intravenously over 30 minutes)
Number of subjects: 41
Study 12145593 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 41
Study 10673879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg i.v.
Number of subjects: 175
Study 10673879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclizine 50 mg i.v.
Number of subjects: 175
Study 10673879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 10673879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclizine vs Ondansetron (for diagnostic laparoscopy)
Number of subjects: 175
Study 10673879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron vs Cyclizine (for laparoscopic sterilization)
Number of subjects: 175
Study 7562882 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg/day before breakfast) for 4 and 8 weeks
Number of subjects: 30
Study 1834827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of teicoplanin (6 mg/kg)
Number of subjects: 24
Study 1834827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of teicoplanin (6 mg/kg)
Number of subjects: 24
Study 1834827 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered by the other route)
Number of subjects: 24
Study 7032534 — intervention group
Group type: EXPERIMENTAL
Intervention: plafibride
Number of subjects: 0
Study 7032534 — intervention group
Group type: COMPARATOR
Intervention: clofibrate
Number of subjects: 0
Study 30948242 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesia 360 (Experimental Group)
Number of subjects: 39
Study 30948242 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 39
Study 26308904 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message for high sensation seekers
Number of subjects: 504
Study 26308904 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message for low sensation seekers
Number of subjects: 504
Study 26308904 — intervention group
Group type: EXPERIMENTAL
Intervention: Message frame fit with viewer's way of thinking
Number of subjects: 504
Study 24000163 — intervention group
Group type: EXPERIMENTAL
Intervention: e-diary (handheld touch screen device)
Number of subjects: 22
Study 24000163 — intervention group
Group type: EXPERIMENTAL
Intervention: electronically read diary (card with predefined slots)
Number of subjects: 22
Study 24000163 — intervention group
Group type: COMPARATOR
Intervention: standard paper diary
Number of subjects: 22
Study 24000163 — intervention group
Group type: EXPERIMENTAL
Intervention: electronic report
Number of subjects: 22
Study 22371069 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine administered at 6 and 12 months (Group 1)
Number of subjects: 197
Study 22371069 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine administered at 12 and 18 months (Group 2)
Number of subjects: 197
Study 22371069 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine administered at 15 and 21 months (Group 3)
Number of subjects: 197
Study 20205331 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 20205331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17627198 — intervention group
Group type: COMPARATOR
Intervention: Healing Touch
Number of subjects: 0
Study 17627198 — intervention group
Group type: COMPARATOR
Intervention: Coaching
Number of subjects: 0
Study 17627198 — intervention group
Group type: COMPARATOR
Intervention: Combined intervention (Healing Touch + Coaching)
Number of subjects: 0
Study 17627198 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (Control)
Number of subjects: 0
Study 16339094 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg
Number of subjects: 762
Study 16339094 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 120 mg
Number of subjects: 762
Study 16339094 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol 300 mg
Number of subjects: 762
Study 16339094 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (combined groups)
Number of subjects: 762
Study 16339094 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol group
Number of subjects: 762
Study 12177641 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 0
Study 12177641 — intervention group
Group type: COMPARATOR
Intervention: Placebo/control
Number of subjects: 0
Study 9883098 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol + Frustration group
Number of subjects: 42
Study 9883098 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 9883098 — intervention group
Group type: EXPERIMENTAL
Intervention: Female subjects
Number of subjects: 42
Study 8267692 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg OD)
Number of subjects: 20
Study 8267692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3715789 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin formulations (300-650 mg)
Number of subjects: 6
Study 31414571 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality disorder
Number of subjects: 201
Study 31414571 — intervention group
Group type: COMPARATOR
Intervention: No personality disorder
Number of subjects: 201
Study 31414571 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 201
Study 29329996 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiflatulent medication
Number of subjects: 78
Study 29329996 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 78
Study 26803422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprocedural stent thrombosis (IPST)
Number of subjects: 6591
Study 26803422 — intervention group
Group type: EXPERIMENTAL
Intervention: No-reflow/slow reflow
Number of subjects: 6591
Study 26803422 — intervention group
Group type: EXPERIMENTAL
Intervention: New/worsened thrombus
Number of subjects: 6591
Study 26803422 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal embolization
Number of subjects: 6591
Study 26803422 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt closure
Number of subjects: 6591
Study 24673048 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm acupuncture therapy
Number of subjects: 90
Study 24673048 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture therapy
Number of subjects: 90
Study 24673048 — intervention group
Group type: COMPARATOR
Intervention: Medication therapy
Number of subjects: 90
Study 22153972 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (4.25±0.38 mg/day)
Number of subjects: 24
Study 22153972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20514506 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic autonomic nerve preservation during rectal cancer surgery
Number of subjects: 17
Study 17680204 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative epidural fentanyl 100 microg
Number of subjects: 40
Study 17680204 — intervention group
Group type: COMPARATOR
Intervention: Control group (without preoperative epidural fentanyl)
Number of subjects: 40
Study 17680204 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received continuous infusion of fentanyl 30 microg x ml(‐1) and 2 mg/ml bupivacaine at a rate of 0.7 ml x h(‐1) for 72 h postoperatively
Number of subjects: 40
Study 16260983 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Group (TG)
Number of subjects: 16
Study 16260983 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 16
Study 11889009 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG group (48 hours of continuous NTG infusion)
Number of subjects: 0
Study 11889009 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitrate therapy)
Number of subjects: 0
Study 11889009 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG group
Number of subjects: 0
Study 10461554 — intervention group
Group type: EXPERIMENTAL
Intervention: High speed ambulance transport
Number of subjects: 54
Study 10461554 — intervention group
Group type: COMPARATOR
Intervention: Smooth ambulance transport
Number of subjects: 54
Study 7502428 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg once daily
Number of subjects: 486
Study 7502428 — intervention group
Group type: COMPARATOR
Intervention: Castration (surgical or medical)
Number of subjects: 486
Study 2038931 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg)
Number of subjects: 24
Study 2038931 — intervention group
Group type: COMPARATOR
Intervention: Topical lidocaine (3 mg/kg)
Number of subjects: 24
Study 7227966 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization for patients with uncomplicated acute myocardial infarction
Number of subjects: 0
Study 7227966 — intervention group
Group type: COMPARATOR
Intervention: Home care with patient monitoring for two hours by a team of technicians dispatched with a specially equipped ambulance
Number of subjects: 0
Study 31078094 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Intervention Program for Alcoholism (IIPA)
Number of subjects: 50
Study 31078094 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 50
Study 27544517 — intervention group
Group type: EXPERIMENTAL
Intervention: PATH+ Intervention
Number of subjects: 238
Study 27544517 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) Control
Number of subjects: 238
Study 25831269 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct SMS message indicating abnormal results and requesting return to clinic
Number of subjects: 385
Study 25831269 — intervention group
Group type: EXPERIMENTAL
Intervention: PIN-protected SMS message
Number of subjects: 385
Study 25831269 — intervention group
Group type: EXPERIMENTAL
Intervention: Coded SMS message ('ABCDEFG')
Number of subjects: 385
Study 25831269 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal SMS message indicating results were normal
Number of subjects: 385
Study 25831269 — intervention group
Group type: EXPERIMENTAL
Intervention: All SMS formats (direct, PIN, coded) for abnormal results
Number of subjects: 385
Study 24103380 — intervention group
Group type: EXPERIMENTAL
Intervention: High n-3 long-chain polyunsaturated fatty acid (LCPUFA) intake
Number of subjects: 2378
Study 21462240 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride 60 mg XR once daily
Number of subjects: 1027
Study 19214891 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocytoscopy (ECS)
Number of subjects: 41
Study 17255844 — intervention group
Group type: EXPERIMENTAL
Intervention: Small volume enemas
Number of subjects: 81
Study 17255844 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 81
Study 15514344 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted collaborative quality improvement intervention
Number of subjects: 6039
Study 15514344 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 6039
Study 11389399 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural hygiene program (11 sessions)
Number of subjects: 106
Study 11389399 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo + no intervention)
Number of subjects: 106
Study 9771983 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler perfusion imaging
Number of subjects: 4
Study 9771983 — intervention group
Group type: COMPARATOR
Intervention: TRUE Test patch test (0.20 mg/cm2 for 48 h)
Number of subjects: 4
Study 8946630 — intervention group
Group type: EXPERIMENTAL
Intervention: Syva MicroTrak EIA
Number of subjects: 328
Study 8946630 — intervention group
Group type: COMPARATOR
Intervention: Syva Direct Specimen Test
Number of subjects: 328
Study 2667388 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 0.5%
Number of subjects: 90
Study 2667388 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain bupivacaine 0.5%
Number of subjects: 90
Study 2667388 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric cinchocaine 0.5%
Number of subjects: 90
Study 1004355 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine 2 mg (sublingual or enteral)
Number of subjects: 43
Study 1004355 — intervention group
Group type: COMPARATOR
Intervention: Isosorbiddinitrate 20 mg (sublingual)
Number of subjects: 43
Study 31996605 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth social communication skills training (TBIconneCT)
Number of subjects: 51
Study 31996605 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person social communication skills training
Number of subjects: 51
Study 31996605 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 51
Study 31706329 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-targeted intervention (video and prompt card)
Number of subjects: 29
Study 31706329 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-targeted intervention (encounter decision aids and training)
Number of subjects: 29
Study 31706329 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 29
Study 29140840 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Voltage Electrical Stimulation (HVES) applied for 60 minutes 3 times per week
Number of subjects: 27
Study 29140840 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (US) applied 3 times per week
Number of subjects: 27
Study 24849310 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (VitE)
Number of subjects: 59
Study 24849310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 24849310 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59
Study 23701973 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex Ayurvedic treatment including tailored combinations of manual treatments, massages, dietary and lifestyle advice, nutritional supplements, yoga posture advice, and knee massage.
Number of subjects: 150
Study 23701973 — intervention group
Group type: COMPARATOR
Intervention: Conventional standard care including self-care advice, pain medication, weight-loss advice (if overweight), and physiotherapy following current international guidelines.
Number of subjects: 150
Study 23701973 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex Ayurvedic treatment
Number of subjects: 150
Study 23701973 — intervention group
Group type: COMPARATOR
Intervention: Conventional standard care
Number of subjects: 150
Study 22028817 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Guard (sodium hypochlorite solution)
Number of subjects: 600
Study 22028817 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium dichloroisocyanurate tablets (Aquatabs)
Number of subjects: 600
Study 22028817 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined flocculant-disinfectant powdered mixture (PUR Purifier of Water)
Number of subjects: 600
Study 22028817 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-coated ceramic siphon filter
Number of subjects: 600
Study 22028817 — intervention group
Group type: COMPARATOR
Intervention: Control group (200 households)
Number of subjects: 600
Study 19019624 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone (ASA 100 mg/d)
Number of subjects: 60
Study 19019624 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel (ASA 100 mg/d + C 75 mg/d)
Number of subjects: 60
Study 17381572 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapleson D breathing system
Number of subjects: 14
Study 17381572 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapleson F breathing system
Number of subjects: 14
Study 17381572 — intervention group
Group type: COMPARATOR
Intervention: TSAA
Number of subjects: 14
Study 15486749 — intervention group
Group type: EXPERIMENTAL
Intervention: Packing of perianal abscess cavity
Number of subjects: 50
Study 15486749 — intervention group
Group type: COMPARATOR
Intervention: Nonpacking of perianal abscess cavity
Number of subjects: 50
Study 12575571 — intervention group
Group type: EXPERIMENTAL
Intervention: Yinfu Decoction (YFD) combined with transfer factor
Number of subjects: 35
Study 12575571 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 35
Study 9847433 — intervention group
Group type: EXPERIMENTAL
Intervention: Rush immunotherapy (RIT)
Number of subjects: 8
Study 8164932 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms misoprostol
Number of subjects: 100
Study 3310722 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release morphine tablets (twice daily)
Number of subjects: 27
Study 3310722 — intervention group
Group type: COMPARATOR
Intervention: Aqueous morphine sulphate (4-hourly)
Number of subjects: 27
Study 31469027 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytic acid drink
Number of subjects: 48
Study 31469027 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 48
Study 29738277 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 29738277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29738277 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 28560947 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF) intervention
Number of subjects: 2148
Study 28560947 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2148